U.S. stock index futures fell on Tuesday after President Donald Trump's plans for potential pharma tariffs renewed fears ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

LLY is bullish in weekly sequence from all time low. It favors rally in (V) after double correction ended at $677.09 low in ...

Ford Motor was the latest to suspend its annual outlook on Monday, joining a host of companies that shelved their forecasts ...

Baron Fifth Avenue Growth Fund declined during the first quarter of 2025, underperforming its benchmark, the Russell 1000 ...

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Investing.com-- U.S. President Donald Trump on Monday signed an executive order aimed at boosting domestic pharmaceutical production, and warned that he will impose import tariffs on the sector in the ...

Branded drug manufacturers, including Eli Lilly and Company (Eli Lilly), have been pursuing various legal actions against compounding pharmacies ...

The order directs the U.S. Food and Drug Administration to reduce the time it takes to approve drug manufacturing plants in ...